The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

New paradigm for drug approval

Forums General Melanoma Community New paradigm for drug approval

  • Post
Viewing 1 reply thread
  • Replies
      Tim–MRF
      Guest

      Peter:

      Everyone I know feels that ipi will be granted accelerated approval.  The FDA cancelled the ODAC for ipi, and said a decision would be made by March 26.  I can't imagine that they would cancel ODAC and then not approve the drug.  Though it could, of course, happen that way.

      The regulatory issues for Ipi and Avastin are different in couple of respects.  The data for ipi have shown overall survival benefit, whereas Avastin can't show that in breast cancer.  And, the treatment options for melanoma are much more limited than in breast cancer. 

      I share many of the concerns raised by the author of the blog you reference.  Clearly we need a regulatory process that is consistent, transparent, and timely.  Moving a therapy from the lab tthrough approval takes a decade or longer.  With medical science changing rapidly, this seems a bit archaic.  What if we could shave a year off that process?  That would translate into thousands of lives saved.

      Tim–MRF

      Loading spinner
      Tim–MRF
      Guest

      Peter:

      Everyone I know feels that ipi will be granted accelerated approval.  The FDA cancelled the ODAC for ipi, and said a decision would be made by March 26.  I can't imagine that they would cancel ODAC and then not approve the drug.  Though it could, of course, happen that way.

      The regulatory issues for Ipi and Avastin are different in couple of respects.  The data for ipi have shown overall survival benefit, whereas Avastin can't show that in breast cancer.  And, the treatment options for melanoma are much more limited than in breast cancer. 

      I share many of the concerns raised by the author of the blog you reference.  Clearly we need a regulatory process that is consistent, transparent, and timely.  Moving a therapy from the lab tthrough approval takes a decade or longer.  With medical science changing rapidly, this seems a bit archaic.  What if we could shave a year off that process?  That would translate into thousands of lives saved.

      Tim–MRF

      Loading spinner
Viewing 1 reply thread
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.